GeneQuine Biotherapeutics, ein Unternehmen das Gentherapie zur Behandlung Gelenkkrankheiten entwickelt, präsentiert bei 12min.MED-Life Science.
Dr. Kilian Guse wird das therapeutische Potential der Gentherapie sowie GeneQuines Entwicklungsprogramme vorstellen. Die Veranstaltungsreihe „12min.MED - Life Science“ fokussiert sich auf die Themen Gesundheit und Medizin und bietet eine Plattform, die neuesten Entwicklungen der wachsenden Branche kennenzulernen.
Im Rahmen ihrer Norddeutschland-Tour hat LaBiotech über GeneQuine einen Film erstellt.
Die LaBiotech Tour ist ein weltweites Projekt mit dem Ziel ausgewählte Biotech-Firmen in Form von Dokumentarfilmen zu präsentieren. Sehen Sie das Interview mit CEO Dr. Kilian Guse über GeneQuines Ziel, die Behandlung von Arthrose zu revolutionieren.
https://www.youtube.com/watch?v=XtYtTtzynSE
February 26th, 2015:
A patent for GeneQuine’s lead products was granted by the European Patent Office, which represents a major milestone in securing intellectual protection in the target markets. The patent covers helper-dependent adenoviral vectors expressing interleukin-1 receptor antagonist and their use in the treatment of osteoarthritis in several species including humans, horses and dogs. Several other corresponding national patent applications are currently being processed worldwide.
GeneQuine was featured as an Emerging Company in the Biocentury journal, the leading provider of biopharma business news, analysis and opinion.
The international Biocentury journal published an article on GeneQuine in their Emerging Company Profile section on December 22, 2014. The article discusses GeneQuine’s gene therapy approach for treatment of osteoarthritis and introduces GeneQuine’s product candidates GQ-201 for horses and GQ-203 for humans. Furthermore, the article points out the adva...
Berlin, November 8, 2014:
GeneQuine was nominated by its investors the High-Tech Gründerfonds to present at the Falling Walls Venture conference along with 27 other international startups. GeneQuine was selected as one of the three finalists and was voted second by a distinguished jury of international industry leaders, strategy consultants and venture capitalist.
11.06.2014
Data of the proof-of-concept study with GeneQuine’s lead candidate GQ-201 were featured in two presentations in May 2014 at the leading gene therapy congress ‘American Society of Gene and Cell Therapy Annual Meeting’. In one of the talks, Dr. Alan Nixon of Cornell University presented the outstanding results of the study and emphasized the potential of the therapy for the treatment of osteoarthritis in horses. Alan Nixon – one of the leading equine surgeons and researchers in equine ...
14.10.2013
The seasoned expert in GMP manufacturing of viral agents, Dr. André Habel, is GeneQuine's newest addition to the management team.
He will be responsible for the development of a robust, scalable GMP manufacturing platform for GeneQuine's gene therapy vectors.
10.10.2013
GeneQuine received a positive decision by EMA's Committee for Medicinal Products for Veterinary Use (CVMP) on classification of GeneQuine's lead candidate GQ-201 as product for minor use or minor species (MUMS).
